Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.76 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.70 |
| ▸ | VCP | P55072 | 2/20 | 0.68 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | CFTR | P13569 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888054 | 0.90 | ALOX5 (0.78) | ALOX5NPY5RVCPAMY1ASMN1; SMN2 | |
| SCHEMBL31126428 | 0.87 | ALOX5 (0.78) | ALOX5NPY5RVCPAMY1ASMN1; SMN2 | |
| SCHEMBL23610351 | 0.86 | ALOX5 (0.76) | ALOX5NPY5RVCPAMY1ASMN1; SMN2 | |
| SCHEMBL2648894 | 0.86 | ALOX5 (1.00) | ALOX5NPY5RVCPAMY1AMAPT | |
| SCHEMBL207658 | 0.85 | MEN1 (0.75) | ALOX5NPY5RVCPSMN1; SMN2MAPT | |
| SCHEMBL31126438 | 0.85 | ALOX5 (0.64) | ALOX5NPY5RVCPSMN1; SMN2CFTR | |
| SCHEMBL5026675 | 0.85 | ALOX5 (0.64) | ALOX5NPY5RVCPSMN1; SMN2CFTR | |
| SCHEMBL23554169 | 0.85 | ALOX5 (0.60) | ALOX5NPY5RVCPAMY1ASMN1; SMN2 | |
| SCHEMBL7267313 | 0.85 | VCP (0.80) | ALOX5NPY5RVCPSMN1; SMN2CFTR | |
| SCHEMBL1821894 | 0.85 | ALOX5 (0.79) | ALOX5NPY5RVCPAMY1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | claimed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | claimed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | claimed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | claimed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | claimed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | claimed |
| US-20240390333-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-11-28 | — | — | US | disclosed |
| CN-107629022-B | Antibacterial synergist and preparation method and application thereof | 上海医药工业研究院 | 2024-11-12 | — | — | CN | disclosed |
| US-11974988-B2 | Neuroprotective compositions and methods of using the same | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-05-07 | — | — | US | disclosed |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-07-08 | — | — | US | disclosed |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-07-08 | — | — | US | disclosed |
| US-9718784-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717709-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9315449-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-9156775-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2637658-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | Duke University (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064715-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | HSF1, HSP90AB1, HSPBP1 | ALOX5 3430/4885NPY5R 3251/4885VCP 1003/4885 |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | ALOX5 3324/4885NPY5R 3734/4885VCP 832/4885 |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | ALOX5 3324/4885NPY5R 3734/4885VCP 832/4885 |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | ALOX5 3324/4885NPY5R 3734/4885VCP 832/4885 |
| US-20210205275-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | GAP43, NLN, SMN1; SMN2 | ALOX5 302/4885NPY5R 1885/4885VCP 1377/4885 |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | ALOX5 3324/4885NPY5R 3734/4885VCP 832/4885 |
| US-11974988-B2 | Neuroprotective compositions and methods of using the same | GAP43, NLN, SMN1; SMN2 | ALOX5 302/4885NPY5R 1885/4885VCP 1377/4885 |
| US-20240390333-A1 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | GAP43, NLN, SMN1; SMN2 | ALOX5 302/4885NPY5R 1885/4885VCP 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.